Surrozen (SRZN) Capital Expenditures (2020 - 2026)
Surrozen (SRZN) recorded quarterly Capital Expenditures of $120000.0 in Q1 2026, down 43.13% quarter-over-quarter from $211000.0 in Q4 2025, and up 344.44% on a YoY basis from $27000.0 in Q1 2025.
Surrozen (SRZN) Capital Expenditures (2020 - 2026) Analysis & Trends
Surrozen's Capital Expenditures history runs 7 years deep, the most recent figure standing at $120000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 344.44% year-over-year to $120000.0; the TTM figure through Mar 2026 stood at $373000.0 (up 1186.21% YoY), while the FY2025 annual figure was $280000.0, up 3011.11% from the prior year.
- Capital Expenditures was $120000.0 for Q1 2026 at Surrozen, down from $211000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $435000.0 in Q2 2022 to a low of -$495000.0 in Q4 2022.
- Historically, Capital Expenditures has averaged $74333.3 across 5 years, with a median of $55000.0 in 2023.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures tumbled 252.78% in 2022, then soared 10450.0% in 2025.
- A 5-year view of Capital Expenditures shows it stood at -$495000.0 in 2022, then jumped by 116.77% to $83000.0 in 2023, then sank by 97.59% to $2000.0 in 2024, then jumped by 10450.0% to $211000.0 in 2025, then plunged by 43.13% to $120000.0 in 2026.
- The last three Capital Expenditures figures came in at $120000.0 (Q1 2026), $211000.0 (Q4 2025), and $24000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 133.40 Mn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -63,220.27 |
| 10 | Surrozen | 239,016.67 | -106.67 Mn | - | 120,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 120,000.00 |
| Mar 31, 2026 | 120,000.00 |
| Dec 31, 2025 | 211,000.00 |
| Dec 31, 2025 | 211,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Sep 30, 2025 | 24,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Jun 30, 2025 | 18,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Mar 31, 2025 | 27,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Dec 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Mar 31, 2024 | 7,000.00 |
| Jun 30, 2023 | 83,000.00 |
| Jun 30, 2023 | 83,000.00 |
| Mar 31, 2023 | 315,000.00 |
| Mar 31, 2023 | 315,000.00 |
| Dec 31, 2022 | -495,000.00 |
| Dec 31, 2022 | -495,000.00 |